Comparison of Dissolution profile for Immediate-Release Dosage form for US and Europe
International Journal of Drug Regulatory Affairs · 2022
DOI: 10.22270/ijdra.v10i2.519 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Regulatory Affairs, 2022. Verfasst von Shivam Kanojiya und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Any oral medication product control strategy must include the creation of a dissolve method with appropriate specifications. In the creation of drug, dissolution testing is critical IV approach. In some cases, an IV dissolution test can be used instead of an in vivo dissolution test. As a result, regulatory agencies have formally acknowledged in vitro methods to determine the dissolution frequency of API from the solid oral form as a significant factor when manufacturing solid-oral-dosage forms. Dissolution tests have long been acknowledged as critical quality-control tools for ensuring batch-to-batch consistency. Following post-approval changes to pharmaceutical products, dissolution testing is also important in providing quality information of the product.
Zitieren
APA
Kanojiya, S., Patel, N., Patel, R. J., & Patel, A. (2022). Comparison of Dissolution profile for Immediate-Release Dosage form for US and Europe. International Journal of Drug Regulatory Affairs. https://doi.org/10.22270/ijdra.v10i2.519
Vancouver
Kanojiya S, Patel N, Patel RJ, Patel A. Comparison of Dissolution profile for Immediate-Release Dosage form for US and Europe. International Journal of Drug Regulatory Affairs. 2022. doi:10.22270/ijdra.v10i2.519
BibTeX
@article{Kanojiya2022,
author = {Kanojiya, Shivam and Patel, Neel and Patel, Ravish J. and Patel, Amit},
title = {Comparison of Dissolution profile for Immediate-Release Dosage form for US and Europe},
journal = {International Journal of Drug Regulatory Affairs},
year = {2022},
doi = {10.22270/ijdra.v10i2.519}
}
EUVIMED